Expert Opinion on Pharmacotherapy

Papers
(The H4-Index of Expert Opinion on Pharmacotherapy is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Pharmacotherapy developments in autophagy inhibitors for bladder cancer48
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children42
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy40
Oral anticoagulation therapy in the setting of liver disease37
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis37
Current treatment options for Mycobacterium marinum cutaneous infections36
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan35
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases32
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy29
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook28
The pharmacological treatment and management of hyperhidrosis26
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease26
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten23
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond23
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives22
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges22
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis21
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma20
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants20
Pharmacotherapeutic options in pediatric obesity: an urgent call for further research20
0.079792976379395